Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$83.1M
77M shares
52-week range
$0.93 – $4.69
4% from low
Sector
WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES
Exchange
NYSE
CS
P/S (TTM)
0.0
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
www.accendrahealth.comNo one on the platform currently holds ACH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 317,913 | $724.8K |
| Execution date | Ratio |
|---|---|
| 2006-10-11 | 4-for-1 |
No one on the platform has traded ACH yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -74.2% | -20.1% | ||||
| Profit Margin % | -39.8% | -8.2% | -4.4% | |||
| Free Cash Flow Margin % | -11.0% | -0.8% | 0.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +93.6% on the P/E track.
At today's price, your expected annual return is +103.1% on the P/E track.
At today's price, your expected annual return is +111.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.5B | -9.9% | $0.02 | $0.01–$0.03 | 56.4× | 3 |
| 2027 | $2.6B | +3.2% | $0.18 | $-0.02–$0.36 | 6.0× | 3 |
| 2028 | $2.7B | +4.2% | $0.32 | $-0.34–$0.98 | 3.4× | 2 |
| 2029 | $2.9B | +6.6% | $0.45 | $0.44–$0.46 | 2.4× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $-0.08 | $-0.19 | -126.6% |
| 2026-05-11 | $-0.06 | $-0.04 | +33.3% |
| 2026-02-19 | $0.22 | $0.21 | -4.5% |
| 2025-10-30 | $0.23 | $0.25 | +8.7% |
| 2025-08-11 | $0.27 | $0.26 | -3.7% |
| 2025-05-08 | $0.20 | $0.23 | +15.0% |
| 2025-02-28 | $0.53 | $0.55 | +3.8% |
| 2024-11-04 | $0.40 |
| $0.42 |
| +5.0% |
| $474M |
| — |
| CGCCanopy Growth Corporation | $0.94 | +1.15% | $396M | — |
| CVRXCVRx, Inc. | $3.00 | +4.17% | $80M | — |
Source: Financial Modeling Prep · peers by sector/industry
$ACH Watchlist Update: Coliseum Capital Files to Sell Most of Its ACH Position. Our thoughts noted in the comment section of our watchlist article: https://www.energyalphaco.com/p/accendra-health-the-debt-has-been
View on StockTwits ↗
$ACH why are they search ING for new ceo IF they go BK:)
View on StockTwits ↗@spaarrow1 I agree that $ACH has substantial upside leverage if the turnaround succeeds, but these projections run well ahead of the current financial evidence. Accendra still has approximately $1.71B of net debt and currently guides to only breakeven/slightly positive 2026 FCF. Becoming debt-free in 18 months would therefore require a dramatic and presently unsupported cash-flow inflection. The $60B cash estimate also cannot reconcile with $2.4B of annual revenue—five years of revenue would total only about $12B before expenses, interest and capex. A $17–$20 share price is not impossible, but it requires higher EBITDA, sustained positive FCF and genuine net-debt reduction. Revenue alone does not establish equity value, particularly with this much leverage. That upside optionality is why $ACH remains interesting—but the unproven cash conversion and deleveraging are why I continue to classify it as a high-risk Watchlist situation.
View on StockTwits ↗
$ACH Guys listen. In 1.5 years this Company is debt free and IF they have 2.4 b revenue a year this Will be a 17-20 usd stock. And after 5 years they can have 60 billion in cash and can accumulate other companies. The this is a 100 usd stock. Imagine a 100x from 1.30 usd/share. This can be a monster stock. But u guys have to stop sellibg/buying. Only buy IF u can afford to be Long. I think this is a hidden gem. But Will Take 1.5 years til they are debt free. They took big loans to buy and improve the Company. This was a 40 usd stock just 3 years ago.
View on StockTwits ↗
$ACH I told u... I told u... Easy money ✅
View on StockTwits ↗$ACH No excuses....if you'd rather slave at a job for it that's ok.... I like it the easy way....awesome alert here onrhr adds.... I got others coming for tomorrow.... Break $1.10 for more here 🪭🪭🪭🪭
View on StockTwits ↗
$ACH Just started a very small position in the premarket. This is positive news in the short term that buys them at least a few more quarters of liquidity and relieves short term pressure of BK. https://finance.yahoo.com/markets/stocks/articles/accendra-health-drops-equity-issuance-122915500.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.